These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 20544639)

  • 21. Rapid progression of amyotrophic lateral sclerosis in an acromegalic patient after surgical resection of a growth hormone-producing pituitary adenoma.
    Mondok A; Aranyi Z; Kovacs GG; Czirjak S; Pusztai P; Varga I; Racz K
    Neurologist; 2010 Sep; 16(5):315-8. PubMed ID: 20827122
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study.
    Colao A; Cappabianca P; Caron P; De Menis E; Farrall AJ; Gadelha MR; Hmissi A; Rees A; Reincke M; Safari M; T'Sjoen G; Bouterfa H; Cuneo RC
    Clin Endocrinol (Oxf); 2009 May; 70(5):757-68. PubMed ID: 19178516
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluctuation analysis of postoperative secretory status in patients operated for acromegaly.
    Graillon T; Castinetti F; Boucekine M; Cuny T; Morange I; Fuentes S; Figarella-Branger D; Albarel F; Brue T; Dufour H
    Ann Endocrinol (Paris); 2020 Feb; 81(1):11-17. PubMed ID: 31982107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acromegaly presenting with diabetic ketoacidosis, associated with retinitis pigmentosa and octreotide-induced bradycardia: a case report and a review of the literature.
    Erem C; Ersöz HO; Ukinç K; Avunduk AM; Hacihasanoglu A; Koçak M
    Endocrine; 2006 Aug; 30(1):145-9. PubMed ID: 17185803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly.
    Mercado M; Borges F; Bouterfa H; Chang TC; Chervin A; Farrall AJ; Patocs A; Petersenn S; Podoba J; Safari M; Wardlaw J;
    Clin Endocrinol (Oxf); 2007 Jun; 66(6):859-68. PubMed ID: 17465997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unusual type of growth hormone-producing pituitary tumor in acromegaly.
    Yamagata S; Kageyama K; Sakihara S; Yamada S; Takayasu S; Chikazawa S; Inoshita N; Sano T; Suda T
    Endocr Pathol; 2012 Sep; 23(3):201-4. PubMed ID: 22638653
    [No Abstract]   [Full Text] [Related]  

  • 27. Transsphenoidal surgery for acromegaly: predicting remission with early postoperative growth hormone assays.
    Sarkar S; Jacob KS; Pratheesh R; Chacko AG
    Acta Neurochir (Wien); 2014 Jul; 156(7):1379-87; discussion 1387. PubMed ID: 24781680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early surgical intervention for patients with possible clinically silent somatotroph adenoma: a case series.
    Kawaguchi T; Ogawa Y; Tominaga T
    J Med Case Rep; 2019 Mar; 13(1):85. PubMed ID: 30862315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly.
    Potorac I; Petrossians P; Daly AF; Alexopoulou O; Borot S; Sahnoun-Fathallah M; Castinetti F; Devuyst F; Jaffrain-Rea ML; Briet C; Luca F; Lapoirie M; Zoicas F; Simoneau I; Diallo AM; Muhammad A; Kelestimur F; Nazzari E; Centeno RG; Webb SM; Nunes ML; Hana V; Pascal-Vigneron V; Ilovayskaya I; Nasybullina F; Achir S; Ferone D; Neggers SJ; Delemer B; Petit JM; Schöfl C; Raverot G; Goichot B; Rodien P; Corvilain B; Brue T; Schillo F; Tshibanda L; Maiter D; Bonneville JF; Beckers A
    Endocr Relat Cancer; 2016 Nov; 23(11):871-881. PubMed ID: 27649724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnosis and management of acromegaly: giant invasive adenoma.
    Cahyanur R; Setyawan W; Sudrajat DG; Setyowati S; Purnamasari D; Soewondo P
    Acta Med Indones; 2011 Apr; 43(2):122-8. PubMed ID: 21785175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly.
    Zhang S; Li Y; Guo X; Gao L; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B
    J Formos Med Assoc; 2018 Jan; 117(1):34-41. PubMed ID: 28341329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. "Spontaneous" reduction of tonsillar herniation in acromegaly: a case report.
    Agostinis C; Caverni L; Montini M; Pagani G; Bonaldi G
    Surg Neurol; 2000 Apr; 53(4):396-9. PubMed ID: 10825527
    [No Abstract]   [Full Text] [Related]  

  • 33. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
    Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A
    Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical experiences and success rates of acromegaly treatment: the single center results of 62 patients.
    Evran M; Sert M; Tetiker T
    BMC Endocr Disord; 2014 Dec; 14():97. PubMed ID: 25511633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sustained improvement in vision in a recurrent growth hormone secreting macroadenoma during treatment with octreotide in the absence of marked tumour shrinkage.
    Lindsay JR; Harding JA; Ellis PK; Sheridan B; Atkinson AB
    Pituitary; 2003; 6(4):209-14. PubMed ID: 15237932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current pharmacotherapy for acromegaly: a review.
    Biermasz NR; Romijn JA; Pereira AM; Roelfsema F
    Expert Opin Pharmacother; 2005 Nov; 6(14):2393-405. PubMed ID: 16259571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical, hormonal and magnetic resonance imaging (MRI) predictors of transsphenoidal surgery outcome in acromegaly.
    Bourdelot A; Coste J; Hazebroucq V; Gaillard S; Cazabat L; Bertagna X; Bertherat J
    Eur J Endocrinol; 2004 Jun; 150(6):763-71. PubMed ID: 15191345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolving criteria for post-operative biochemical remission of acromegaly: can we achieve a definitive cure? An audit of surgical results on a large series and a review of the literature.
    Minniti G; Jaffrain-Rea ML; Esposito V; Santoro A; Tamburrano G; Cantore G
    Endocr Relat Cancer; 2003 Dec; 10(4):611-9. PubMed ID: 14713271
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigation into the efficacy and safety of octreotide LAR in Japanese patients with acromegaly: Shizuoka study.
    Oki Y; Inoue T; Imura M; Tanaka T; Genma R; Iwabuchi M; Hataya Y; Matsuzawa Y; Iino K; Nishizawa S; Nakamura H
    Endocr J; 2009; 56(9):1095-101. PubMed ID: 19755754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Outcome of surgical treatment for acromegaly performed by a single neurosurgeon and cumulative meta-analysis].
    Boeving A; Borba LA; Rodrigues AM; Orichowski EB; Paz Filho GJ; Santos CM; Boguszewski CL
    Arq Bras Endocrinol Metabol; 2006 Oct; 50(5):884-92. PubMed ID: 17160212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.